Osteogenic Osteosarcoma of the Calvaria following Radiotherapy for Cerebellar Astrocytoma: Report of a Case in Childhood

1985 ◽  
Vol 71 (4) ◽  
pp. 391-396 ◽  
Author(s):  
Leopoldo Casentini ◽  
Alfonso Visonà ◽  
Federico Colombo ◽  
Vincenzo Stracca Pansa ◽  
Franco Pozza ◽  
...  
Keyword(s):  
Malignant Neoplasm ◽  
Rare Occurrence ◽  
Pertinent Literature ◽  
Second Malignant Neoplasm ◽  
Cerebellar Astrocytoma

Sarcoma as a second malignant neoplasm following radiotherapy is a rare occurrence in childhood. A case of osteogenic osteosarcoma of temporoparietal bone that developed 56 months after irradiation for a cerebellar astrocytoma in a 10-year-old child is reported and the pertinent literature is briefly reviewed. The possibility of an association (in the same patient) between these two rather uncommon lesions is extremely unlikely. Therefore, it is possible that radiotherapy played a role in the induction of the sarcoma. The indolent course of the latter is stressed.

Breast cancer as second malignant neoplasm after acute myeloid leukemia: A rare occurrence

2016 ◽  
Vol 5 (4) ◽  
pp. 333 ◽  
Author(s):  
SmithaCarol Saldanha ◽  
Govind Babu ◽  
MallekavuSuresh Babu ◽  
LakshmaiahChinnagiriyappa Kuntegowdanahalli ◽  
LakkavalliKrishnappa Rajeev ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Malignant Neoplasm ◽  
Rare Occurrence ◽  
Second Malignant Neoplasm ◽  
Acute Myeloid

Second malignant neoplasms in children treated for rhabdomyosarcoma. Intergroup Rhabdomyosarcoma Study Committee.

1993 ◽  
Vol 11 (2) ◽  
pp. 262-270 ◽  
Author(s):  
R Heyn ◽  
V Haeberlen ◽  
W A Newton ◽  
A H Ragab ◽  
R B Raney ◽  
...  
Keyword(s):  
Cumulative Incidence ◽  
Alkylating Agent ◽  
Age Groups ◽  
Malignant Neoplasm ◽  
Bone Sarcoma ◽  
Incidence Density ◽  
Malignant Neoplasms ◽  
Tumor Type ◽  
Second Malignant Neoplasm ◽  
Li Fraumeni Syndrome

PURPOSE This study was performed to determine the incidence and risk factors involved in the development of a second malignant neoplasm (SMN) after treatment of primary rhabdomyosarcoma (RMS) in patients enrolled onto Intergroup Rhabdomyosarcoma Studies I and II (IRS I and II). PATIENTS AND METHODS There were 1,770 patients with primary RMS entered onto IRS I and II between 1972 and 1984. They were treated with chemotherapy and, in most instances, radiotherapy according to randomized or assigned regimens based on clinical grouping. Median follow-up time for these patients was 8.4 years. Incidence density (ID) was calculated for each study and for treatment and age groups. The 10-year cumulative incidence was estimated for each study. RESULTS Twenty-two SMNs have been reported through 1991. The most common tumor type was a bone sarcoma followed by acute nonlymphoblastic leukemia (ANLL). The median time to the development of an SMN was 7 years (range, 1 11/12 to 15 9/12 years). The 10-year cumulative incidence rate was 1.7% for both studies. ID and cumulative incidence estimates were highest for patients who received both an alkylating agent and radiotherapy. The majority of patients for whom family histories were available had either neurofibromatosis themselves or a family history that suggested the Li-Fraumeni syndrome (LFS). CONCLUSION The results of this study suggest that genetic abnormalities play a prominent role in the development of an SMN after therapy for a primary RMS. Chemotherapy with an alkylating agent and radiotherapy play significant roles in the development of an SMN compared with patients who received only one of these therapeutic modalities.

scholarly journals Colorectal adenocarcinoma as a second malignant neoplasm following rhabdomyosarcoma of the urinary bladder: a case report

2000 ◽  
Vol 15 (4) ◽  
pp. 475 ◽  
Author(s):  
Sung Shin Park ◽  
Byoung Kwon Kim ◽  
Chong Jai Kim ◽  
Woo Sun Kim ◽  
In One Kim ◽  
...  
Keyword(s):  
Case Report ◽  
Urinary Bladder ◽  
Colorectal Adenocarcinoma ◽  
Malignant Neoplasm ◽  
Second Malignant Neoplasm

Malignant melanoma as second malignant neoplasm in long-term childhood cancer survivors: A systematic review

2012 ◽  
Vol 58 (5) ◽  
pp. 665-674 ◽  
Author(s):  
Katja. I. Braam ◽  
Annelies Overbeek ◽  
Gertjan J.L. Kaspers ◽  
Cecile M. Ronckers ◽  
Annette Y.N. Schouten-van Meeteren ◽  
...  
Keyword(s):  
Systematic Review ◽  
Malignant Melanoma ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Malignant Neoplasm ◽  
Childhood Cancer Survivors ◽  
Second Malignant Neoplasm

Long-term incidence of venous thromboembolism (VTE) among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10562-10562
Author(s):  
Arin L Madenci ◽  
Brent Weil ◽  
Qi Liu ◽  
Todd M. Gibson ◽  
Yutaka Yasui ◽  
...  
Keyword(s):  
High Risk ◽  
Childhood Cancer ◽  
Chronic Conditions ◽  
Malignant Neoplasm ◽  
Cancer Recurrence ◽  
Care Providers ◽  
Second Malignant Neoplasm ◽  
Increased Risk ◽  
Survivors Of Childhood Cancer

10562 Background: This study aimed to estimate the incidence of late-occurring VTE among survivors of childhood cancer, and to identify associated demographic and clinical factors that define high-risk subgroups for potential screening and prevention. Methods: Using data from CCSS, a multi-institutional, longitudinal cohort of 5-year survivors of childhood cancer (diagnosed 1970-1999) and their siblings, the primary endpoint of self-reported late VTE (occurring ≥5 years after diagnosis) was estimated using multivariable piecewise exponential models adjusted for age, sex, and race. Generalized estimating equations accounted for potential within-family correlation where applicable. Results: Among 23,601 survivors and 5051 siblings, the incidence of VTE was 1.15 and 0.48 events per 1000 person-years, respectively. For survivors, median age at last follow-up was 28.6 years (range 5.6-58.3) and median follow-up time from diagnosis was 21.2 years (range 5.0-39.3). The adjusted rate ratio (RR) for survivors compared to siblings was 2.2 (95% confidence interval [CI] = 1.7-2.8, P< 0.01). Among survivors, risk factors for VTE included BMI≥30kg/m2 (ref. BMI 18.5-24.5; RR = 1.5, CI = 1.2-2.0, P< 0.01), increasing number of severe or life-threatening (i.e. CTCAE grades 3 or 4) non-VTE chronic conditions (ref. 0 conditions; 1-2 conditions: RR = 2.5, CI = 2.0-3.1, P< 0.01 ; ≥3 conditions: RR = 3.5, CI = 2.5-4.9, P< 0.01), and cancer recurrence or second malignant neoplasm (RR = 3.5, CI = 2.7-4.6, P< 0.01). Incidence of late VTE was associated with increased subsequent mortality, independent of non-VTE chronic conditions (RR 2.2, 95% CI = 1.7-2.8, P< 0.01). Conclusions: Survivors of childhood cancer remain at increased risk for VTE across their lifespan. While typically not causal, late VTE was associated with subsequent mortality. Care providers should be aware of this increased risk and consider interventions that target modifiable co-morbidities such as obesity. Surveillance and education should be directed toward high-risk survivors.

Sign in / Sign up

Export Citation Format

Share Document